Skip to main content
Karolinska Development logo

Karolinska Development — Investor Relations & Filings

Ticker · KDEV ISIN · SE0002190926 LEI · 54930011ZA52NKO5W681 ST Financial and insurance activities
Open in API
Filings indexed 761 across all filing types
Latest filing 2019-08-29 Capital/Financing Update
Country SE Sweden
Listing ST KDEV

About Karolinska Development

https://www.karolinskadevelopment.com/en

Karolinska Development is an investment company specializing in the life sciences sector. It identifies, finances, and supports the creation and growth of companies developing innovative medical technologies and pharmaceuticals. The firm manages a diversified portfolio of biotechnology and medtech ventures, often originating from academic research, with the goal of developing ground-breaking treatments for severe diseases. Karolinska Development leverages its team's expertise in research, development, and commercialization to guide its portfolio companies, providing both capital and strategic support to advance innovations toward the market.

Recent filings

Filing Released Lang Actions
Karolinska Development extends the subscription period in the directed share issue to holders of the Company’s convertible loan
Capital/Financing Update Classification · 1% confidence The document is a press release announcing an extension to the subscription period for a 'Directed share issue' related to convertible loan holders. This action directly concerns the company's capital structure and financing activities (issuing new shares to settle debt). This aligns best with the 'Capital/Financing Update' category (CAP). Although it is a press release, the core subject matter is a specific financing event, not just a general announcement of report publication (RPA) or a miscellaneous regulatory filing (RNS). The document details the extension, the reason (negotiations), and the new timeline, making it substantive information about a capital change.
2019-08-29 English
Karolinska Development förlänger teckningsperioden i den riktade nyemissionen till Bolagets konvertibelinnehavare
Capital/Financing Update Classification · 1% confidence The document is a press release from Karolinska Development AB dated August 29, 2019. The core subject is the extension of the subscription period for a directed new share issue (nyemission) aimed at convertible note holders. This action directly relates to changes in the company's capital structure and fundraising activities. Based on the definitions, the most appropriate classification is 'Capital/Financing Update' (CAP), as it details an ongoing financing event (the directed new share issue) and an adjustment to its timeline. It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), but a specific announcement about capital structure modification.
2019-08-29 Swedish
Karolinska Development extends the subscription period in the directed share issue to holders of the Company’s convertible loan
Share Issue/Capital Change Classification · 1% confidence The document is a press release announcing an extension to the subscription period for a directed share issue related to a convertible loan. This action directly concerns the company's capital structure and fundraising activities. Based on the definitions, this falls under 'Capital/Financing Update' (CAP). It is not an Annual Report (10-K), an Earnings Release (ER), or a Dividend Notice (DIV). The document is an announcement detailing a change in financing terms, making CAP the most appropriate classification.
2019-08-29 English
Karolinska Development's portfolio company Promimic receives FDA approval for its HAnano Surface® on a spinal implant
Regulatory Filings Classification · 1% confidence The document is a press release issued by Karolinska Development regarding a portfolio company's FDA approval. It is short (3126 characters), provides a summary of the news, and includes a link to an attachment titled 'KD Press release Promimic Aug 2019'. According to the 'Menu vs Meal' rule, since this is a short announcement of a development and includes an attachment link, it is classified as a Regulatory Filing (RNS) as it serves as a general corporate announcement that does not fit into more specific categories like financial reports or governance disclosures.
2019-08-28 English
Karolinska Development's portfolio company Promimic receives FDA approval for its HAnano Surface® on a spinal implant
Regulatory Filings Classification · 1% confidence The document is a press release issued by Karolinska Development regarding a portfolio company's FDA approval. It is short (3126 characters), provides a summary of the news, and includes a link to an attachment titled 'KD Press release Promimic Aug 2019'. According to the 'Menu vs Meal' rule, since this is a short announcement of a development and includes an attachment link, it is classified as a Regulatory Filing (RNS) as it serves as a general corporate announcement that does not fit into more specific categories like financial reports or governance disclosures.
2019-08-28 English
Karolinska Development's portfolio company Promimic receives FDA approval for its HAnano Surface® on a spinal implant
Regulatory Filings Classification · 1% confidence The document is a press release issued by Karolinska Development regarding a portfolio company's FDA approval. It is short (3126 characters), provides a summary of the news, and includes a link to an attachment titled 'KD Press release Promimic Aug 2019'. According to the 'Menu vs Meal' rule, since this is a short announcement of a development and includes an attachment link, it is classified as a Regulatory Filing (RNS) as it serves as a general corporate announcement that does not fit into more specific categories like financial reports or governance disclosures.
2019-08-28 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.